Търсене на изпитвания

Активни:

Намерени 4,781 изпитвания Стр. 207 от 240

Активно (без набиране)

Feasibility Trial of a Guided Internet-delivered Intervention for Adolescents With ADHD

ADHD

The main aim of this feasibility trial is to investigate the feasibility and preliminary clinical outcomes of a guided digital intervention for adolescents with ADHD. Adolescents with ADHD will be enrolled in a 6-week digital intervention including weekly therapist contact. The adolescents and their parents will be asked to complete self-report questionnaires at pre-, during, post- and 3- and 6-months follow-up.

Начало: 18.11.2024 Край: 01.11.2026 Възраст: 13–16 г.

Norway Haukeland University Hospital NCT06711224

Активно (без набиране)

Vegetables for All Project in Uganda

Vegetable Consumption

This study is an evaluation of the Global Alliance for Improved Nutrition (GAIN)'s Vegetables for All Project in Uganda. The aim of this program is to improve access to safe and fresh vegetables in FitFood Zones (FFZs) and generate demand for vegetables through a media campaign and FFZ branding. RTI and local partners will conduct impact and process evaluations of GAIN's program. The evaluation will include a mix of quantitative and qualitative methods and will be guided by the RE-AIM (reach, effectiveness, adoption, implementation, and maintenance) evaluation framework.

Начало: 15.11.2024 Край: 15.12.2026 Възраст: от 18 г.

Uganda RTI International NCT06602752

Активно (без набиране)

Leverage Noninvasive Transcutaneous Vagus Nerve Stimulation to Reduce Suicidal Behaviors in Vulnerable Adolescents

Self Harm Suicidal Ideation

Suicidal thoughts, suicide attempts, and suicide are increasingly common in adolescence. Current face-to-face prevention approaches are of limited effectiveness, rely on extensive resources, and are at odds with adolescents' digital preferences. We will evaluate two unconventional but promising interventions delivered to 13- to 17-year-olds: transcutaneous vagus nerve stimulation to target emotion dysregulation, and a peer-support smartphone app to combat social isolation. If effective, these digitally-delivered interventions could reach far more adolescents at far lower cost than current approaches.

Начало: 15.11.2024 Край: 30.09.2027 Възраст: 13–17 г.

United States University of Notre Dame NCT05602779

Активно (без набиране) Фаза 2

A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

The purpose of this study is to support the registration plan of sonrotoclax plus zanubrutinib treatment in participants with previously untreated chronic lymphocytic leukemia (CLL). This study is designed to assess the contribution of sonrotoclax to the efficacy outcome of the combination of zanubrutinib and sonrotoclax.

Начало: 14.11.2024 Край: 01.09.2029 Възраст: от 18 г.

Brazil, China, Italy +3 BeOne Medicines NCT06637501

Активно (без набиране) Фаза 4

A Study on Safety and Effectiveness of Long-term Treatment With Vamorolone in Boys With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

This study aims to assess safety and effectivness of long-term treatment with vamorolone in boys with Duchenne Muscular Dystrophy (DMD) who have completed prior studies with vamorolone.

Начало: 10.11.2024 Край: 01.09.2028 Лечение

Belgium, Czechia, Greece +6 Santhera Pharmaceuticals NCT06713135

Активно (без набиране)

Treatment Response to TFESI and DRG Pulsed RF in Lumbar Spinal Stenosis and Disc Herniation

Lumbar Radiculopathy Lumbar Disc Herniation Lumbar Spinal Stenosis (LSS)

Lumbar radiculopathy caused by conditions such as lumbar disc herniation (LDH) and lumbar spinal stenosis (LSS) can lead to chronic pain and reduced quality of life. In patients who do not respond to conservative treatments, minimally invasive procedures such as transforaminal epidural steroid injection (TFESI) and pulsed radiofrequency (pRF) applied to the dorsal root ganglion (DRG) are commonly used. This study aims to compare treatment responses between patients with lumbar disc herniation and those with lumbar spinal stenosis who have undergone TFESI combined with dorsal root ganglion pulsed radiofrequency. Pain levels and clinical outcomes will be evaluated to determine whether the underlying condition affects treatment effectiveness. The results of this study may help guide clinicians in selecting the most appropriate treatment approach for patients with lumbar radiculopathy.

Начало: 01.11.2024 Край: 01.06.2026 Възраст: 18–75 г.

Turkey (Türkiye) Marmara University NCT07509580

Активно (без набиране) Фаза 1

A Study of ZW191 in Participants With Solid Tumors

Advanced Solid Tumors

The purpose of this study is to find out if ZW191 is safe and can treat participants with advanced cancers, including ovarian, endometrial, and non-small cell lung cancers.

Начало: 30.10.2024 Край: 01.01.2027 Възраст: от 18 г. Лечение

Australia, Japan, Singapore +3 Zymeworks BC Inc. NCT06555744

Активно (без набиране) Фаза 2

A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

Glioma

The purpose of this study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy. Your participation could last approximately 11 months and possibly longer depending upon how you and your tumor respond.

Начало: 25.10.2024 Край: 01.02.2028 Възраст: до 20 г. Лечение

Australia, Belgium, Denmark +7 Eli Lilly and Company NCT06413706

Активно (без набиране) Фаза 2

A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight

Obesity Overweight or Obesity

This study is designed to test how well MET097, an active drug, works to treat individuals with obesity or overweight when compared to placebo. MET097 or placebo will be given to individuals weekly for 28 weeks. If an individual is assigned to MET097 they will receive one of four different dose levels. Participants who have completed the first 28 weeks may participate in an exploratory extension study.

Начало: 24.10.2024 Край: 01.05.2026 Възраст: 18–70 г.

United States Metsera, a wholly owned subsidiary of Pfizer NCT06712836

Активно (без набиране) Фаза 1

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Pancreatic Ductal Adenocarcinoma Non-small Cell Lung Cancer Colorectal Cancer Advanced Solid Tumor +1

The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alone or in combination with other treatments. The study will have 2 parts: monotherapy dose escalation and dose optimization. The study is expected to last up to approximately 5 years.

Начало: 21.10.2024 Край: 01.01.2030 Възраст: от 18 г.

Belgium, China, France +6 Eli Lilly and Company NCT06607185

Активно (без набиране) Фаза 2

A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine

Herpes Zoster (HZ) Infectious Diseases Shingles

The goal of this clinical trial is to assess the safety and immunogenicity of an srRNA-based vaccine, JCXH-105, in the prevention of Herpes Zoster (Shingles). Subjects will be randomized to receive either JCXH-105 or Shingrix.

Начало: 16.10.2024 Край: 01.08.2026 Възраст: от 50 г.

United States Immorna Biotherapeutics, Inc. NCT06581575

Активно (без набиране) Фаза 3

To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

This is a randomized, double-blind, placebo-controlled clinical trial with 500 participants. In this study, the safety evaluation used the common toxic reaction criteria of the National Cancer Institute to evaluate the adverse events of the drugs, and the effectiveness evaluation used the eczema area and severity score and the overall investigator score to confirm the efficacy.

Начало: 08.10.2024 Край: 01.06.2026 Възраст: 18–75 г.

China Shanghai Chia Tai Tianqing Pharmaceutical Technology De NCT06552520

Активно (без набиране)

At-Home Exercise Study for Veterans With Healed Diabetic Foot Ulcers

Diabetic Foot Ulcer

Foot ulcers and amputations are a common and feared complication for people with diabetes. People with a diabetic foot ulcer have a higher risk of dying within five years than people with diabetes without an ulcer. At least one in four people with a new diabetic foot ulcer will die within five years, largely due to cardiovascular causes. The reasons for this increased mortality involve decreased mobility. People with a recently healed diabetic foot ulcer are considered "in remission" as opposed to "cured" because the underlying medical problems which led to their ulcer are still present. Once in remission, the current standard of care is to slowly increase ambulation. The problem is that people rarely return to the recommended level of mobility. The ability to safely maintain mobility with aging is critical. This pilot study is a small clinical trial to test the feasibility and acceptability of a home-based exercise regimen. The investigators will also assess if this home-based exercise regimen can increase mobility and function without increasing diabetic foot ulcer recurrence by improving lower extremity strength, lower extremity tissue perfusion and glycemic control.

Начало: 01.10.2024 Край: 31.03.2027 Възраст: от 50 г.

United States VA Office of Research and Development NCT06312579

Активно (без набиране)

Pulsed-Field Ablation With/Without Electrogram Mapping

Non-paroxysmal Atrial Fibrillation

Pulsed field ablation (PFA) has demonstrated favorable safety and efficacy in atrial fibrillation ablation, particularly for pulmonary vein isolation (PVI). However, the optimal PFA-based ablation strategy for non-paroxysmal atrial fibrillation remains uncertain. In addition to anatomical lesion sets such as PVI and posterior wall isolation (PWI), Electrogram Mapping of Key Substrates may allow identification of residual arrhythmogenic areas that contribute to the maintenance of atrial fibrillation. In the investigators' previously completed single-center cohort study, adjunctive ablation targeting key substrates identified by electrogram mapping on top of PVI+PWI was feasible and associated with improved rhythm outcomes. This prospective multicenter randomized controlled study is designed to compare PFA-based PVI+PWI alone versus PVI+PWI plus adjunctive ablation guided by Electrogram Mapping of Key Substrates in patients with non-paroxysmal atrial fibrillation, in order to evaluate the efficacy and safety of this strategy in a broader and more rigorous clinical setting.

Начало: 30.09.2024 Край: 01.06.2028 Възраст: 18–80 г.

China, United States Xu Liu NCT07541989

Активно (без набиране) Фаза 1

A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV

Respiratory Syncytial Virus (RSV) Infectious Disease

The goal of this clinical trial is to assess the safety, reactogenicity and immunogenicity of an mRNA-based vaccine, JCXH-108, the prevention of Respiratory Syncytial Virus (RSV) infection and diseases. Participants will be randomized to receive either JCXH-108 or placebo.

Начало: 25.09.2024 Край: 01.06.2026 Възраст: от 18 г.

United States Immorna Biotherapeutics, Inc. NCT06564194

Активно (без набиране) Фаза 3

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer KRAS G12C Lung Cancer

The purpose of this study is to assess the safety and efficacy of divarasib compared to locally approved KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung cancer (NSCLC).

Начало: 23.09.2024 Край: 30.11.2029 Възраст: от 18 г. Лечение

Argentina, Australia, Austria +23 Hoffmann-La Roche NCT06497556

Активно (без набиране) Фаза 1

A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment

Lymphomas Non-Hodgkin's B-Cell Precursor Cell Lymphoblastic Leukemia-Lymphoma

The purpose of this first-in-human study is to evaluate the safety and tolerability of INT2104 when administered to humans in a broad population of participants with refractory/relapsing B-cell malignancies. Preliminary efficacy information may also be obtained. INT2104 is a gene therapy delivering a transgene for a chimeric antigen receptor (CAR) specific for CD20 (CAR20). The lentiviral vector is designed to generate CAR T and CAR Natural Killer (NK) cells inside the body following intravenous (IV) administration. Study details include the following: * The study duration will be 5 years * The treatment duration will be a one-time intravenous (IV) infusion of INT2104

Начало: 20.09.2024 Край: 01.07.2026 Възраст: от 18 г. Лечение

Australia, Spain Kite, A Gilead Company NCT06539338

Активно (без набиране) Фаза 4

The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products

Respiratory Syncytial Virus Infection

Respiratory Syncytial Virus (RSV) is the leading cause of lower respiratory tract infections (LRTIs) in infants and young children. It is also a leading cause of mortality in children \

Начало: 19.09.2024 Край: 31.05.2026 Възраст: 18–45 г.

United States National Institute of Allergy and Infectious Diseases ( NCT06551506

Активно (без набиране) Ранна Фаза 1

Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

This study is evaluating INCB081776 when given in combination with the checkpoint inhibitor pembrolizumab and palliative radiation therapy in patients with metastatic or recurrent metastatic or recurrent head and neck squamous cell carcinoma (HNSCC). 12 participants will be enrolled and can expect to be on study for up to 12 months.

Начало: 18.09.2024 Край: 31.08.2027 Възраст: от 18 г.

United States University of Wisconsin, Madison NCT06308913

Активно (без набиране) Фаза 1/2

NS-050/NCNP-03 in Boys With DMD (Meteor50)

Duchenne Muscular Dystrophy

This is a Phase 1/2 study of Multiple-Ascending Dose (MAD) levels for 12 weeks of treatment followed by 24 weeks of open-label treatment with a selected dose of NS-050/NCNP-03 administered once weekly to ambulant boys with DMD, who have a DMD exon deletion amenable to exon 50 skipping.

Начало: 18.09.2024 Край: 01.03.2028 Възраст: 4–15 г.

Canada, Japan, South Korea +2 NS Pharma, Inc. NCT06053814

1 … 205 206 207 208 209 … 240